GlobeNewswire: Canntab Therapeutics Limited Contains the last 10 of 12 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T07:22:34ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/03/28/1781274/0/en/Canntab-Therapeutics-Announces-Engagement-of-Relations-Publiques-Paradox-Inc-for-Investor-Relations-Services.html?f=22&fvtc=4&fvtv=42118Canntab Therapeutics Announces Engagement of Relations Publiques Paradox Inc. for Investor Relations Services2019-03-28T12:30:00Z<![CDATA[NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.]]>https://www.globenewswire.com/news-release/2019/02/28/1744162/0/en/Canntab-Enters-into-Five-Year-Supply-and-Loan-Agreement-with-FSD-Pharma-and-World-Class-Extractions-on-Organic-Hemp-Deal.html?f=22&fvtc=4&fvtv=42118Canntab Enters into Five Year Supply and Loan Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal2019-02-28T12:00:00Z<![CDATA[TORONTO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Canntab Therapeutics Limited (CSE: PILL, OTCQB: CTABF, FSE: TBF1) (“Canntab” or the “Company”) is pleased to announce that it has entered into a supply and loan agreement (the “Agreement”) with FSD Pharma Inc. (“FSD”) and World Class Extractions Inc. (“World Class”) (collectively, the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the Agreement, the Supplier grants the Purchasers the right and option to purchase up to CAD $5.0 million of the Supplier’s hemp crop for a period of 5 years commencing in 2019 at a purchase price of CAD $100.0 per kg per 1% of CBD extracted from the flower.]]>https://www.globenewswire.com/news-release/2019/02/20/1738029/0/en/Canntab-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=42118Canntab Provides Corporate Update2019-02-20T04:30:00Z<![CDATA[TORONTO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Canntab Therapeutics Limited (CSE: PILL, OTCQB: CTABF, FSE: TBF1) (“Canntab” or the “Company”) is pleased to provide an update on a number of significant developments, including that it has commenced converting a portion of its facility situated within the Health Canada approved facilities owned by FSD Pharma Inc. (“FSD Pharma”), which recently received its Standard Processing License, its previously announced financial advisory agreement with Mackie Research Capital Corporation (“Mackie Research”) has been extended, one of its directors, Vitor Fonseca, has advised the Company of his intention to transfer a portion of his equity through the exercise of options in the Company strictly for estate planning purposes to members of his family, and it it has begun trading on the OTCQB Venture Market.]]>https://www.globenewswire.com/news-release/2019/02/12/1720684/0/en/Canntab-Enters-into-Supply-Agreement-with-FSD-Pharma-and-World-Class-Extractions-on-Organic-Hemp-Deal.html?f=22&fvtc=4&fvtv=42118Canntab Enters into Supply Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal2019-02-12T12:30:00Z<![CDATA[Canntab enters into 3-way supply agreement to purchase up to 1,000 kg of 2018 hemp crop Canntab enters into 3-way supply agreement to purchase up to 1,000 kg of 2018 hemp crop]]>https://www.globenewswire.com/news-release/2018/12/05/1662369/0/en/Canntab-Enters-Into-a-Binding-Term-Sheet-With-Leading-Orthopaedic-Surgeon-Dr-Don-Garbuz-M-D-for-a-Clinical-Research-Trial-of-Canntab-s-Tablets.html?f=22&fvtc=4&fvtv=42118Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets2018-12-05T13:00:00Z<![CDATA[NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.]]>https://www.globenewswire.com/news-release/2018/11/14/1651707/0/en/Canntab-Announces-Correction-to-Press-Release.html?f=22&fvtc=4&fvtv=42118Canntab Announces Correction to Press Release 2018-11-14T19:07:51Z<![CDATA[NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.]]>https://www.globenewswire.com/news-release/2018/11/14/1651293/0/en/Canntab-Corporate-Update.html?f=22&fvtc=4&fvtv=42118Canntab Corporate Update2018-11-14T12:41:14Z<![CDATA[TORONTO, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”) is a company with a clear vision of becoming the leader in solid oral dosage formulation of cannabis. Their unique products offer advantages to the medical community, patients, adult use consumers and governments. Canntab is pleased to provide this corporate update to its shareholders.]]>https://www.globenewswire.com/news-release/2018/10/31/1640103/0/en/Canntab-to-Enter-Medicinal-Cannabis-Market-in-Mexico.html?f=22&fvtc=4&fvtv=42118Canntab to Enter Medicinal Cannabis Market in Mexico2018-10-31T11:30:00Z<![CDATA[NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.]]>https://www.globenewswire.com/news-release/2018/10/19/1624118/0/en/Canntab-Files-Application-to-Become-Licensed-Producer.html?f=22&fvtc=4&fvtv=42118Canntab Files Application to Become Licensed Producer2018-10-19T14:22:56Z<![CDATA[TORONTO, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Canntab Therapeutics Limited (CSE:PILL) (“Canntab” or the “Company”), a leader in the development of precision oral dose cannabis tablets and capsules, is pleased to announce that it has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the “License”), and that it received confirmation from Health Canada that its application had been received. The License, if granted by Health Canada, would allow the Company to process cannabis products at its current production facility in Markham, Ontario with minimal additional capital expenditures as compared to a new purpose-built facility.]]>https://www.globenewswire.com/news-release/2018/01/15/1289356/0/en/Telferscot-and-Canntab-Therapeutics-Execute-Definitive-Agreement.html?f=22&fvtc=4&fvtv=42118Telferscot and Canntab Therapeutics Execute Definitive Agreement2018-01-15T15:15:15Z<![CDATA[TORONTO, Jan. 15, 2018 (GLOBE NEWSWIRE) -- Telferscot Resources Inc. (CSE:TFS) (“Telferscot”) and Canntab Therapeutics Limited (“Canntab”) (and together the “Parties”) are pleased to announce execution of an Amalgamation Agreement (the “Agreement”) between the Parties pursuant to the Agreement. Canntab will amalgamate with a wholly-owned subsidiary of Telferscot and the Canntab shareholders will receive common shares of Telferscot in consideration for their shares of Canntab (the “Amalgamation”). Canntab has completed its $5-million financing, which was one of the conditions precedent to closing pursuant to the Agreement. The Parties have also satisfied the due diligence set forth in the Agreement and will be filing a listing statement with the Canadian Securities Exchange (“CSE”) for their review, comment and approval. This Listing Statement will provide detailed disclosure of the new business and related risk factors. The transaction proposed will constitute a Fundamental Change pursuant to CSE policies.]]>